BMS’ Opdivo cleared for monthly use
US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option for the immunotherapy of every four weeks.
Read More
Tag: sBLA
Janssen seeks to expand use of multiple myeloma drug
Janssen Biotech is seeking to expand the scope of Darzalex as a second-line combination treatment for multiple myeloma.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
